Advertisement

Novel pleiotropic BRCA2 pathogenic variants in Lebanese families

      Highlights

      • Novel BRCA2 mutations in two Lebanese families.
      • Variable expressivity within family members.
      • Haploinsufficiency and/or mutation-specific dominant negative phenotypes.

      Abstract

      BRCA1 and BRCA2 associated pathogenic variants are the major cause of familial cases of early onset breast and ovarian cancers. Here we report two novel heterozygous pathogenic variants in exons 18 and 11 of the BRCA2 gene in two Lebanese families. The double nucleotide insertion c.8052_8053dupAA was identified in a 38-year-old Lebanese woman diagnosed with a breast cancer. The patient had a family history of affected first degree relatives. The double nucleotide deletion c.4342_4343delAA was identified in a 67-year-old woman with ovarian cancer. The patient came from a family marked by the occurrence of variable cancers. Her two daughters were also found to carry the deleterious variant. Both genetic aberrations result in a framing error that leads to a premature stop codon giving rise to unstable or truncated proteins. We further discuss two non-mutually exclusive potential scenarios related to the resulting haploinsufficiency and variant-specific dominant negative phenotype that might explain, at least in part, the variable expressivity associated with BRCA2 pathogenic variants.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Thorslund T.
        • McIlwraith M.J.
        • Compton S.A.
        • Lekomtsev S.
        • Petronczki M.
        • Griffith J.D.
        • et al.
        The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.
        Nat Struct Mol Biol. 2010; 17: 1263-1265https://doi.org/10.1038/nsmb.1905
        • Roy R.
        • Chun J.
        • Powell S.N.
        BRCA1 and BRCA2: different roles in a common pathway of genome protection.
        Nat Rev Cancer. 2011; 12: 68-78https://doi.org/10.1038/nrc3181
        • Lord C.J.
        • Ashworth A.
        Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
        Nat Med. 2013; 19: 1381-1388https://doi.org/10.1038/nm.3369
        • Stefansson O.A.
        • Jonasson J.G.
        • Johannsson O.T.
        • Olafsdottir K.
        • Steinarsdottir M.
        • Valgeirsdottir S.
        • et al.
        Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
        Breast Cancer Res BCR. 2009; 11: R47https://doi.org/10.1186/bcr2334
        • Willers H.
        • Taghian A.G.
        • Luo C.-M.
        • Treszezamsky A.
        • Sgroi D.C.
        • Powell S.N.
        Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
        Mol Cancer Res MCR. 2009; 7: 1304-1309https://doi.org/10.1158/1541-7786.MCR-09-0149
        • Schlacher K.
        • Christ N.
        • Siaud N.
        • Egashira A.
        • Wu H.
        • Jasin M.
        Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.
        Cell. 2011; 145: 529-542https://doi.org/10.1016/j.cell.2011.03.041
        • Mijic S.
        • Zellweger R.
        • Chappidi N.
        • Berti M.
        • Jacobs K.
        • Mutreja K.
        • et al.
        Replication fork reversal triggers fork degradation in BRCA2-defective cells.
        Nat Commun. 2017; 8: 859https://doi.org/10.1038/s41467-017-01164-5
        • Narod S.A.
        Modifiers of risk of hereditary breast cancer.
        Oncogene. 2006; 25: 5832-5836https://doi.org/10.1038/sj.onc.1209870
        • Hall M.J.
        • Reid J.E.
        • Burbidge L.A.
        • Pruss D.
        • Deffenbaugh A.M.
        • Frye C.
        • et al.
        BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
        Cancer. 2009; 115: 2222-2233https://doi.org/10.1002/cncr.24200
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • Phillips K.-A.
        • Mooij T.M.
        • Roos-Blom M.-J.
        • et al.
        Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        JAMA. 2017; 317: 2402-2416https://doi.org/10.1001/jama.2017.7112
        • Garber J.E.
        • Offit K.
        Hereditary cancer predisposition syndromes.
        J Clin Oncol Off J Am Soc Clin Oncol. 2005; 23: 276-292https://doi.org/10.1200/JCO.2005.10.042
        • Lux M.P.
        • Fasching P.A.
        • Beckmann M.W.
        Hereditary breast and ovarian cancer: review and future perspectives.
        J Mol Med Berl Ger. 2006; 84: 16-28https://doi.org/10.1007/s00109-005-0696-7
        • Langston A.A.
        • Malone K.E.
        • Thompson J.D.
        • Daling J.R.
        • Ostrander E.A.
        BRCA1 mutations in a population-based sample of young women with breast cancer.
        N Engl J Med. 1996; 334: 137-142https://doi.org/10.1056/NEJM199601183340301
        • Chen S.
        • Parmigiani G.
        Meta-analysis of BRCA1 and BRCA2 penetrance.
        J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25: 1329-1333https://doi.org/10.1200/JCO.2006.09.1066
        • Liede A.
        • Karlan B.Y.
        • Narod S.A.
        Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
        J Clin Oncol Off J Am Soc Clin Oncol. 2004; 22: 735-742https://doi.org/10.1200/JCO.2004.05.055
        • Sopik V.
        • Phelan C.
        • Cybulski C.
        • Narod S.A.
        BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
        Clin Genet. 2015; 87: 411-418https://doi.org/10.1111/cge.12497
        • Cicenas J.
        • Kvederaviciute K.
        • Meskinyte I.
        • Meskinyte-Kausiliene E.
        • Skeberdyte A.
        • Cicenas J.
        KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer.
        Cancers. 2017; 9https://doi.org/10.3390/cancers9050042
        • Moynahan M.E.
        • Pierce A.J.
        • Jasin M.
        BRCA2 is required for homology-directed repair of chromosomal breaks.
        Mol Cell. 2001; 7: 263-272
        • Carreira A.
        • Hilario J.
        • Amitani I.
        • Baskin R.J.
        • Shivji M.K.K.
        • Venkitaraman A.R.
        • et al.
        The BRC Repeats of BRCA2 Modulate the DNA-binding selectivity of RAD51.
        Cell. 2009; 136: 1032-1043https://doi.org/10.1016/j.cell.2009.02.019
        • Sy S.M.H.
        • Huen M.S.Y.
        • Chen J.
        PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
        Proc Natl Acad Sci U S A. 2009; 106: 7155-7160https://doi.org/10.1073/pnas.0811159106
        • Serrano-Fernández P.
        • Dębniak T.
        • Górski B.
        • Bogdanova N.
        • Dörk T.
        • Cybulski C.
        • et al.
        Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
        Breast Cancer Res Treat. 2009; 117: 161-165https://doi.org/10.1007/s10549-008-0249-1